Healios (Drug Discovery) Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 82

Employees

  • Stock Symbol
  • 4593

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $1.24
  • (As of Friday Closing)

Healios (Drug Discovery) General Information

Description

Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.

Contact Information

Formerly Known As
Retina Institute Japan
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 15th Floor, Toranomon Hills Business Tower
  • 1-17-1 Toranomon, Minato-ku
  • Tokyo, 100-0006
  • Japan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
TKS
Vertical(s)
Corporate Office
  • 15th Floor, Toranomon Hills Business Tower
  • 1-17-1 Toranomon, Minato-ku
  • Tokyo, 100-0006
  • Japan

Healios (Drug Discovery) Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Healios (Drug Discovery) Stock Performance

As of 20-Nov-2026, Healios (Drug Discovery)’s stock price is $1.24. Its current market cap is $167M with 135M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.24 $1.32 $1.20 - $3.19 $167M 135M 1.74M -$0.10

Healios (Drug Discovery) Financials Summary

As of 30-Sep-2026, Healios (Drug Discovery) has a trailing 12-month revenue of $299K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 203,160 177,986 85,616 69,489
Revenue 299 695 3,698 861
EBITDA (29,311) (20,485) (16,824) (22,447)
Net Income (16,603) (14,813) (27,963) (27,208)
Total Assets 145,036 109,022 90,371 107,459
Total Debt 23,625 16,698 16,959 32,135
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Healios (Drug Discovery) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Healios (Drug Discovery)‘s full profile, request access.

Request a free trial

Healios (Drug Discovery) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manuf
Drug Discovery
Tokyo, Japan
82 As of 2026

Geneva, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Healios (Drug Discovery) Competitors (1)

One of Healios (Drug Discovery)’s competitors is MindMaze Therapeutics Holding, a Formerly PE-Backed company based in Geneva, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
MindMaze Therapeutics Holding Formerly PE-Backed Geneva, Switzerland
You’re viewing 1 of 1 competitors. Get the full list »

Healios (Drug Discovery) Patents

Healios (Drug Discovery) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-7909737-B1 Apparatus for absorbent articles Active 25-Nov-2025
EP-4756013-A1 Method for producing natural killer cells Pending 02-Aug-2023
WO-2025028596-A1 Method for producing natural killer cells Inactive 02-Aug-2023
JP-2026502608-A Cryogenic storage device and method Pending 16-Jan-2023
EP-4652419-A1 Cryostorage devices and methods Pending 16-Jan-2023 F25D29/001
To view Healios (Drug Discovery)’s complete patent history, request access »

Healios (Drug Discovery) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Healios (Drug Discovery) Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Healios (Drug Discovery)‘s full profile, request access.

Request a free trial

Healios (Drug Discovery) Investments & Acquisitions (3)

Healios (Drug Discovery)’s most recent deal was a Merger/Acquisition with Athersys for . The deal was made on 04-Apr-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Athersys 04-Apr-2024 Merger/Acquisition Biotechnology
Athersys 30-Apr-2018 PIPE Biotechnology
Sighregen 28-Feb-2014 Joint Venture Drug Discovery
To view Healios (Drug Discovery)’s complete investments and acquisitions history, request access »

Healios (Drug Discovery) ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

41.7 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Healios (Drug Discovery)’s complete esg history, request access »

Healios (Drug Discovery) Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Athersys Cleveland, OH 1995

Healios (Drug Discovery) FAQs

  • When was Healios (Drug Discovery) founded?

    Healios (Drug Discovery) was founded in 2011.

  • Where is Healios (Drug Discovery) headquartered?

    Healios (Drug Discovery) is headquartered in Tokyo, Japan.

  • What is the size of Healios (Drug Discovery)?

    Healios (Drug Discovery) has 82 total employees.

  • What industry is Healios (Drug Discovery) in?

    Healios (Drug Discovery)’s primary industry is Drug Discovery.

  • Is Healios (Drug Discovery) a private or public company?

    Healios (Drug Discovery) is a Public company.

  • What is Healios (Drug Discovery)’s stock symbol?

    The ticker symbol for Healios (Drug Discovery) is 4593.

  • What is the current stock price of Healios (Drug Discovery)?

    As of 20-Nov-2026 the stock price of Healios (Drug Discovery) is $1.24.

  • What is the current market cap of Healios (Drug Discovery)?

    The current market capitalization of Healios (Drug Discovery) is $167M.

  • What is Healios (Drug Discovery)’s current revenue?

    The trailing twelve month revenue for Healios (Drug Discovery) is $299K.

  • Who are Healios (Drug Discovery)’s competitors?

    MindMaze Therapeutics Holding is a competitor of Healios (Drug Discovery).

  • What is Healios (Drug Discovery)’s annual earnings per share (EPS)?

    Healios (Drug Discovery)’s EPS for 12 months was -$0.10.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process